While the new Shield blood test may motivate more people to get screened for colorectal cancer, it also comes with downsides, ...
Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly ...
Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug Administration in July.
As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...
New data from cancer screening and diagnostic test provider Exact Sciences have shown an 88.3% sensitivity rate for its blood-based colorectal cancer screening test.
A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...
“A blood-based colorectal cancer screening test that can detect advanced precancerous lesions ... Exact Sciences plans to use these results to support an FDA submission and approval and to ...
“A blood-based colorectal cancer screening test that can detect advanced precancerous lesions ... BLUE-C study that will be submitted to the FDA. In the BLUE-C study results, performance ...
Blood tests for cancer detection, known as liquid biopsies, can still be unreliable, but progress is being made. Competition between different diagnostics companies is also intensifying.